Retrospective ONCare Alliance Network data showed lower odds of new or worsened hypertension with acalabrutinib versus ibrutinib (OR 0.27; 95% CI, 0.074–0.98). Despite older age and higher baseline ...
Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free ...
The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted ...
The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results